Soleno Therapeutics, Inc.

DB:6XC Stock Report

Market Cap: €3.4b

Soleno Therapeutics Management

Management criteria checks 1/4

Soleno Therapeutics' CEO is Anish Bhatnagar, appointed in Jan 2017, has a tenure of 8.33 years. total yearly compensation is $51.16M, comprised of 1.3% salary and 98.7% bonuses, including company stock and options. directly owns 1.04% of the company’s shares, worth €34.92M. The average tenure of the management team and the board of directors is 1.4 years and 5.9 years respectively.

Key information

Anish Bhatnagar

Chief executive officer

US$51.2m

Total compensation

CEO salary percentage1.25%
CEO tenure8.3yrs
CEO ownership1.0%
Management average tenure1.4yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Anish Bhatnagar's remuneration changed compared to Soleno Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$198m

Dec 31 2024US$51mUS$640k

-US$176m

Sep 30 2024n/an/a

-US$131m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$4mUS$557k

-US$39m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$1mUS$557k

-US$24m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$4mUS$538k

-US$31m

Sep 30 2021n/an/a

-US$31m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$3mUS$504k

-US$25m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$822kUS$470k

-US$31m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$952kUS$460k

-US$12m

Compensation vs Market: Anish's total compensation ($USD51.16M) is above average for companies of similar size in the German market ($USD2.39M).

Compensation vs Earnings: Anish's compensation has increased whilst the company is unprofitable.

CEO

Anish Bhatnagar (54 yo)

8.3yrs

Tenure

US$51,160,430

Compensation

Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since 2017 and serves as its President and Chief Operating Officer. He serves as Chairman of Soleno sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Anish Bhatnagar
Chairman8.3yrsUS$51.16m1.04%
€ 34.9m
James MacKaness
CFO & Compliance Officer5.5yrsUS$8.77m0.18%
€ 6.1m
Patricia Hirano
Senior Vice President of Regulatory Affairsno dataUS$6.05m0.021%
€ 710.0k
Meredith Manning
Chief Commercial Officer1.3yrsUS$7.79m0.023%
€ 784.3k
Jesse Schumaker
General Counselless than a yearno datano data
Lauren Budesheim
Vice President of People1.3yrsno datano data
Kristen Yen
Senior Vice President of Global Clinical Operations and Patient Advocacyno dataUS$821.67k0.056%
€ 1.9m
Neil Cowen
Senior Vice President of Drug Development8.2yrsno datano data
Michael Huang
Senior Vice President of Clinical Development1.5yrsno data0.073%
€ 2.5m
Mitchell Nagao
Senior Vice President of Medical Affairs1.3yrsno datano data

1.4yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 6XC's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anish Bhatnagar
Chairman11.3yrsUS$51.16m1.04%
€ 34.9m
James Arthur Geraghty
Member of Advisory Board1.3yrsno datano data
William Harris
Independent Director10.9yrsUS$360.16k0.018%
€ 593.9k
Thomas Casale
Member of Advisory Boardno datano datano data
Andrew Sinclair
Independent Director6.4yrsUS$290.16k0.013%
€ 433.8k
Robert Christensen
Member of Advisory Boardno datano datano data
Vinod Bhutani
Member of Advisory Boardno datano datano data
Birgitte Volck
Independent Director5.9yrsUS$347.66k0.014%
€ 470.2k
Glenis Scadding
Member of Advisory Boardno datano datano data
Matthew Pauls
Lead Independent Director1.8yrsUS$354.32k0%
€ 0
Shamim Ruff
Chair of the Development Advisory Board1.3yrsno datano data
David Stevenson
Member of Advisory Boardno datano datano data

5.9yrs

Average Tenure

62yo

Average Age

Experienced Board: 6XC's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 00:03
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soleno Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
François BriseboisCraig-Hallum Capital Group LLC